A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.
Also called NCT05552326
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 446 participants
- Sponsor
- Registry
-
NCT05552326 -
2022-501420-20
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Greece, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05552326. Randomized; triple masking; primary purpose treatment. Start 2022-08-31 (actual); primary completion 2024-12-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Olezarsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05552326- Content hash
01fee9c728cd5f8267d33730e76fa41dbb1824a4aea268b2038be5c1e973a804